Solid Biosciences Inc. (SLDB)
3.11
-0.20 (-6.04%)
At close: Jan 14, 2025, 3:59 PM
3.03
-2.57%
Pre-market Jan 15, 2025, 04:39 AM EST
undefined% (undefined)
| Bid | 2.96 |
| Market Cap | 124.26M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -3.04 |
| PE Ratio (ttm) | -1.02 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.1 |
| Volume | 354,784 |
| Avg. Volume (20D) | 383,118 |
| Open | 3.35 |
| Previous Close | 3.31 |
| Day's Range | 3.04 - 3.36 |
| 52-Week Range | 3.04 - 15.05 |
| Beta | undefined |
About SLDB
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technol...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 26, 2018
Employees 88
Stock Exchange NASDAQ
Ticker Symbol SLDB
Website https://www.solidbio.com
Analyst Forecast
According to 11 analyst ratings, the average rating for SLDB stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 414.47% from the latest price.
Buy 90.91%
Hold 0.00%
Sell 0.00%
1 week ago ·
Source
+2.81%
Solid Biosciences shares are trading higher after ...
Unlock content with
Pro Subscription
1 week ago ·
Source
-4.39%
Solid Biosciences shares are trading higher after the company announced FDA clearance of its IND application for a dual-route gene therapy to treat Friedreich's Ataxia.
